<DOC>
	<DOCNO>NCT01902004</DOCNO>
	<brief_summary>The propose project evaluate role neuroimaging biomarkers brain aging ( i.e. , neurodegenerative vascular brain change ) mild cognitive impairment pattern treatment response memantine combine escitalopram compare escitalopram placebo .</brief_summary>
	<brief_title>Brain Aging Treatment Response Geriatric Depression</brief_title>
	<detailed_description>This study design conduct double-blind placebo-controlled trial Namenda ( Memantine ) augmentation Lexapro ( Escitalopram ) depress old adult 60 year age older . Throughout course study , investigator anticipate screen 400 subject recruit 134 participant first four year . This study require subject complete 20 ( twenty ) visit 12 ( twelve ) month study site participation . The purpose study determine whether Namenda ( memantine ) take combination Lexapro ( escitalopram ) , may improve quality treatment response make faster complete , also improve think memory comparison Lexapro take placebo . Enrolled subject provide 10-20 mg escitalopram 12 month , concurrently randomly assign either memantine placebo group . The investigator also examine safety tolerability ( well treatment work side effect ) combination Namenda Lexapro compare placebo Lexapro subject major depressive disorder mild cognitive impairment least 60 year age . Memantine likely accelerate enhance antidepressant response escitalopram improve cognitive performance . Subjects amnestic mild cognitive impairment biomarkers brain age baseline likely preferential response combination memantine escitalopram compare escitalopram placebo , thus identify personalize treatment approach high-risk subgroup poor clinical outcome .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<criteria>Meets DSM 5 criterion major depressive disorder ( recurrent nonrecurrent course identify ) Score 20 high 24item Hamilton Rating Scale Depression ( HDRS ) study entry Score 24 high MiniMental State Exam ( MMSE ) Age 60 year old old History psychiatric illness substance abuse disorder unipolar depression , diagnose prior onset first depressive episode Presence psychotic symptom Severe acute medical illness ( e.g. , major surgery , metastatic cancer , stroke , heart attack ) 6 month prior study entry Acute suicidal violent behavior history suicide attempt within year prior study entry Presence delirium , neurodegenerative dementia , Parkinson 's disease , central nervous system ( CNS ) diseases Toxic metabolic abnormality laboratory examination Medications take medical illness present could account depression Active heart failure categorize Class III great accord New York Heart Association criterion Heart attack crescendo angina within 3 month prior study entry Symptomatic cardiac arrhythmia symptomatic , hemodynamically significant mitral aortic valvular disease Resting heart rate le 50 beat per minute correct QT ( QTc ) interval great 0.45 second Second third degree atrioventricular block Systolic blood pressure great 180 mmHg less 90 mmHg diastolic blood pressure great 105 mmHg less 50 mmHg study entry Treated depot neuroleptic therapy within 6 month prior study entry Treated neuroleptic , antidepressant , anxiolytic medication ( lorazepam ) , overthecounter CNSactive medication use treatment depression ( e.g , St. John 's Wort , kavakava , melatonin ) within 2 week ( 4 week fluoxetine monoamineoxidase inhibitor [ MAOIs ] ) prior first administration study medication Known allergy escitalopram memantine history ineffective treatment escitalopram memantine current depressive episode Requires concomitant therapy prescription overthecounter medication potentially dangerous interaction either escitalopram memantine Requires electroconvulsive therapy ( ECT ) receive ECT within 3 month prior study entry Initiated psychotherapy within 3 month prior study entry initiate terminate psychotherapy study</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Major Depression</keyword>
	<keyword>Geriatric Major Depression</keyword>
	<keyword>Executive Cognitive Dysfunction</keyword>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Older Adults</keyword>
	<keyword>Geriatric</keyword>
	<keyword>Executive Cognitive Impairment</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Disability</keyword>
	<keyword>Comorbidity</keyword>
	<keyword>Medical Burden</keyword>
	<keyword>Safety</keyword>
	<keyword>Candidate Genes</keyword>
</DOC>